Clinical Trial Update: Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial update investigating a predictive biomarker for the efficacy and safety of combining chemotherapy with tislelizumab in NSCLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Hao Long | Conditions: Tislelizumab, Safety | Phase 2 | Status: UNKNOWN